Boston Scientific Announces FDA Clearance for New IQ™ Guide Wire
(October 13, 2004) -- Boston Scientific Corporation (NYSE: BSX) announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its new coronary IQ™ Guide Wire in the United States. The Company will launch the product immediately.

A guide wire is a thin, flexible wire that can be used to facilitate the placement of balloon catheters or other interventional therapeutic devices during coronary angioplasty or other intravascular interventional procedures. The Company's IQ Guide Wire is designed to provide physicians exceptional control in a variety of situations. The Company also announced the availability of the IQ Marker Guide Wire, which features two 5 mm markers. Both the IQ and the IQ Marker Guide Wires are available in 185 and 300 cm lengths, and in both straight and J-tip configurations. The IQ Guide Wire complements Boston Scientific's PT2™ Guide Wire, which is designed for use in more difficult cases such as tight lesions or multi-vessel disease.

"Often, devices undergo changes that show promise on paper, but don't pan out in clinical practice," said Stephen P. Wiet, M.D., and Medical Director of the Cardiac Catheterization Lab at Advocate Christ Medical Center in Oak Lawn, Illinois. "The IQ Guide Wire blends characteristics of several individual guide wires into a versatile workhorse version that delivers outstanding performance in clinical application. The result is a high-tech performance boost to our interventional practice."

"The launch of the IQ Guide Wire means Boston Scientific now has a guide wire to meet all of our customers' needs," said Paul LaViolette, Senior Vice President and Group President, Cardiovascular. "It's further evidence of our long-standing commitment to providing innovative solutions to interventional cardiologists and their patients."

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit:

This press release contains forward-looking statements. The Company wishes to caution the reader of this press release that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, reimbursement policies, commercialization of new technologies, intellectual property, and other factors described in the Company's filings with the Securities and Exchange Commission.